Penumbra Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. Thanks for joining us at the 21st Annual Needham Healthcare Conference. I'm Mike Matson, and I lead the Medtech [and Lead] Research team here at Needham & Company. With me is Penumbra's CEO, Adam Elsesser; and Executive Vice President of Strategy, Jason Mills. Instead a standard presentation, we are going to do a Q&A session. (Operator Instructions)
So we're going to go straight into the Q&A here.
Questions & Answers
I just want to start off with some questions on the Vascular business. Obviously, that's been a tremendous success story for Penumbra, very, very strong growth over the last few years, despite the pandemic.
So just in terms of this growth, I was wondering if you could maybe just talk about what's been driving it? And is it really just simply an under-penetrated market and procedures being converted from tPA
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
